Characteristics, retention and readmissions of opioid-dependent clients treated with oral naltrexone

被引:10
作者
Bartu, A
Freeman, NC
Gawthorne, GS
Allsop, SJ
Quigley, AJ
机构
[1] Curtin Univ Technol, Perth, WA 6001, Australia
[2] Drug & Alcohol Off, Perth, WA, Australia
[3] Drug & Alcohol Serv, Perth, WA, Australia
关键词
drug treatment centres; naltrexone; opioid-dependence; treatment retention;
D O I
10.1080/0959523021000023180
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
The aims of this study were to examine the retention rates of opioid-dependent clients treated with oral naltrexone and identify factors that influence retention in treatment of 981 opioid-dependent clients at a public out-patient clinic in Perth, Western Australia. The average retention period for all clients was 9.0 weeks. The factors associated with longer retention were being employed and referral source. Clients who were employed stayed significantly longer in treatment than unemployed clients. Clients referred from a private clinic were retained in treatment significantly longer than those referred from other sources ((X) over bar = 10.3 vs. 5.9 weeks). While the majority (80.8%) had one admission to naltrexone treatment, 19.2% presented for readmission, some on three or more occasions in the study period. The median period between the end of the first episode of treatment and commencement of the second was 15.6 weeks. The median period between the end of the second episode of treatment and commencement of the third was 11.4 weeks. Those employed had a higher probability of being retained longer in treatment than those who were unemployed in subsequent treatment episodes. Clinicians should expect that initial retention in naltrexone is likely to be relatively short, and that a substantial proportion of clients will represent for further treatment.
引用
收藏
页码:335 / 340
页数:6
相关论文
共 23 条
[1]   MULTIPLE FAMILY-THERAPY AND NALTREXONE IN THE TREATMENT OF OPIATE DEPENDENCE [J].
ANTON, RF ;
HOGAN, I ;
JALALI, B ;
RIORDAN, CE ;
KLEBER, HD .
DRUG AND ALCOHOL DEPENDENCE, 1981, 8 (02) :157-168
[2]  
BELL J, INTERIM CLIN GUIDELI
[3]   A pilot study of naltrexone-accelerated detoxification in opioid dependence [J].
Bell, JR ;
Young, MR ;
Masterman, SC ;
Morris, A ;
Mattick, RP ;
Bammer, G .
MEDICAL JOURNAL OF AUSTRALIA, 1999, 171 (01) :26-30
[4]   THE TREATMENT OF HEROIN-ADDICTION - NALTREXONE ALONE AND WITH BEHAVIOR-THERAPY [J].
CALLAHAN, EJ ;
RAWSON, RA ;
MCCLEAVE, B ;
ARIAS, R ;
GLAZER, M ;
LIBERMAN, RP .
INTERNATIONAL JOURNAL OF THE ADDICTIONS, 1980, 15 (06) :795-807
[5]  
CAPONE T, 1986, J CLIN PSYCHOL, V42, P825, DOI 10.1002/1097-4679(198609)42:5<825::AID-JCLP2270420526>3.0.CO
[6]  
2-B
[7]   An open trial of naltrexone for opiate dependence [J].
Foy, A ;
Sadler, C ;
Taylor, A .
DRUG AND ALCOHOL REVIEW, 1998, 17 (02) :167-174
[8]   Accelerated withdrawal from methadone maintenance therapy using naltrexone and minimal sedation: a case-series analysis [J].
Glasgow, NJ ;
Taylor, J ;
Bell, JR ;
Young, MR ;
Bammer, G .
DRUG AND ALCOHOL REVIEW, 2001, 20 (02) :213-221
[9]   NALTREXONE - A SHORT-TERM TREATMENT FOR OPIATE DEPENDENCE [J].
GREENSTEIN, RA ;
OBRIEN, CP ;
MCLELLAN, AT ;
WOODY, GE ;
GRABOWSKI, J ;
LONG, M ;
COYLEPERKINS, G ;
VITTOR, A .
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 1981, 8 (03) :291-300
[10]   PREDICTORS OF FAVORABLE OUTCOME FOLLOWING NALTREXONE TREATMENT [J].
GREENSTEIN, RA ;
EVANS, BD ;
MCLELLAN, AT ;
OBRIEN, CP .
DRUG AND ALCOHOL DEPENDENCE, 1983, 12 (02) :173-180